Porto Biomedical Journal

Review

Dynamic nuclear polarisation: The future of imaging in oncology?

Eva M. Serrao [a,b,*], Kevin M. Brindle [a,b]

[a] Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
[b] Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA, UK

ARTICLE INFO

ABSTRACT

As clinical oncology evolves with new treatment options becoming available, there is an increasing demand on anatomic imaging for the assessment of patients at different stages. Imaging with hyper-polarized ^{13}C-labelled cell substrates has the potential to become a powerful tool in many steps of clinical evaluation, offering a new metabolic metric and therefore a more personalised approach to treatment response. This articles explores the metabolic basis and potential for translation of hyperpolarised pyruvate as a dynamic nuclear polarisation probe in clinical oncology.

© 2017 PBJ-Associação Porto Biomedical/Porto Biomedical Society. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

New advances in a wide range of fields from genomics to medical imaging are allowing patients to be treated and monitored more precisely and effectively and in ways that better meet their individual needs. Development of tools to truly personalise healthcare will improve our ability to predict and account for individual differences in disease diagnosis, experience, and therapy response. An increased understanding of the relationship between molecular knowledge and conventional anatomical imaging, using molecular imaging (MI), is allowing diagnostic imaging to become more specific and sensitive. The ability to non-invasively assess metabolism *in vivo* and in real time was made possible recently in humans, for the first time, through the use of dynamic nuclear polarisation (DNP) of ^{13}C-labelled metabolites, which could be detected *in vivo* using magnetic resonance spectroscopic imaging (MRSI). This article explores the metabolic basis and potential for translation of [1-^{13}C]pyruvate as a DNP probe in clinical oncology. A subset of cancers is also discussed.

Metabolic changes in cancer: probing glycolysis with hyperpolarized [1-^{13}C]pyruvate

Metabolic reprogramming, namely increased glycolysis, is a well-recognised and highly prevalent hallmark of cancer.[1,2] Since its first report in cancer cells under aerobic conditions, by Otto Warburg in the 1930s,[3,4] numerous additional experimental observations have verified this same phenomenon, which was named the "Warburg effect" over the following decades.[5] From a bioenergetic standpoint glycolysis is an inefficient process to produce energy as it makes only 2 adenosine triphosphate (ATP) molecules per glucose molecule compared to the 38 ATP molecules that complete oxidation produces. Additionally, formation and release of metabolic products, such as hydrogen ions (H^+), to the extracellular space leads to an acidic and potentially toxic environment for cells.[6,7] At a first glance, this selection for inefficient substrate metabolism seems counterintuitive. However, a growing clinical and pre-clinical body of knowledge has revealed the relevance and advantage of this metabolic phenotype in cancer cell survival, namely in providing tumours with a powerful proliferative and invasive advantage over surrounding normal tissues.[2,8] Increased glycolysis enables not only the generation of intermediates and cofactors essential for proliferation but also the alteration of the extra-cellular pH, specifically environmental acidosis, that facilitates invasion through destruction of adjacent normal cell populations, degradation of the extracellular matrix and promotion of angiogenesis.[2,8]

As an almost universal cancer signature, glycolysis is a very attractive pathway to probe either pre-clinically or clinically. While positron emission tomography (PET) with computed tomography (CT) has been the metabolic imaging method most familiar to

G Model
PBJ-53; No. of Pages 5

ARTICLE IN PRESS

2   E.M. Serrao, K.M. Brindle / Porto Biomed. J. 2017;xxx(xx):xxx–xxx

clinicians, other imaging techniques based on MR also exist. [1-^{13}C]pyruvate is the best-established metabolite in the DNP field and the only one so far that has successfully translated to the clinic.[9] Another DNP probe, which also probes glycolysis, is ^{13}C labelled glucose which allows not only assessment of glycolytic flux but also flux into the pentose phosphate pathway (PPP).[10]

Pyruvate has a central role in cell metabolism. In cancer, pyruvate is mostly reversibly reduced by nicotinamide adenine dinucleotide[11] into lactate, in a reaction catalysed by the enzyme lactate dehydrogenase[12] or transaminated by glutamate to produce alanine in the reaction catalysed by alanine transaminase (ALT).[13] These reactions can be probed in vivo and in real time using hyperpolarized [1-^{13}C]-pyruvate.

Basic principles of dynamic nuclear polarisation

DNP significantly (>10,000-fold) increases the signal from and therefore the sensitivity of detection of injected ^{13}C-labelled compounds in vivo.[14] The process involves mixing ^{13}C-labelled molecules with small quantities of a stable radical, cooling the mixture to approximately 1 K in a magnetic field and irradiating the electron spins with microwave irradiation resulting in transfer of the polarisation from the fully polarised electron spins on the radical to the ^{13}C nuclei. The compound is then rapidly dissolved in hot pressurised buffer, and can then be injected into a cell suspension or an animal or a human being in a separate imaging magnet.[15,16] The hyperpolarized signal, however, is transient and lasts in vivo for about 2–3 min, depending on the substrate.[17]

The application of this powerful approach has allowed in vivo imaging of metabolites and their enzymatic conversion into other species, at high temporal and relatively high spatial resolutions.[14,18]

Translation to humans

One of the most challenging milestones for hyperpolarized substrates was achieved with [1-^{13}C]pyruvate with its successful translation to humans in a study in prostate cancer. This imaging proof-of-principle study showed not only the feasibility of HP [1-^{13}C]pyruvate as an agent for noninvasively characterising metabolic alterations in tumours but also its safety in humans.[9] However, this technique is still in its infancy and many hurdles will need to be addressed if it is to realise a clinical role within the toolkit of existing competing clinical techniques.

Biologically, a better understanding of the relationship between the DNP image data, specific enzymatic reactions and malignancy would greatly benefit the hyperpolarized field. Further advances in our understanding of cancer biology have revealed increasing tumour heterogeneity, which significantly increases in complexity in the clinical setting. One interesting point would be to depict this heterogeneity with imaging. However, again, studies on the biological-imaging relationship are needed.

The clinical application of this technique in a daily basis will also need to be refined for reliable results to be acquired. Mirroring other metabolic imaging techniques that are already used routinely in the clinic, i.e. ^{18}Fluorodeoxyglucose (^{18}F-FDG) PET, improved variability of hyperpolarized [1-^{13}C]-pyruvate was shown when subjects were fasted.[19] However this result will have to be validated in humans.

At a technical level current research has focused on improving methods for fast imaging, analyzing kinetic data, and the development of methods for increasing the hyperpolarized signal lifetime.[20] Improved hyperpolarizer designs, which use automated injection systems[21] and higher field-strengths[22] will improve the substrate polarisation levels at the time of injection. Further,

new methods to accelerate pyruvate polarisation can also be applied.[23,24] Chemical derivatization to enhance tissue uptake[25] and prolongation of the polarisation lifetime by deuteration[10] may also allow the use and development of new agents.

Potential of DNP in current clinical practice

From the very first reports HP [1-^{13}C]pyruvate has proved to be a very promising probe in the oncology field, with great potential to be applied in many of the clinical patient management steps.[26] Preclinically, hyperpolarized [1-^{13}C]pyruvate has been reported as an interesting screening tool for early detection and secondary screening of pancreatic cancer[27] (Fig. 1). In another study, [1-^{13}C]pyruvate detected metabolic changes prior to tumour formation.[28] In the clinic, increased lactate labelling was also observed in histologically confirmed areas of prostate cancer that were not identifiable by conventional ^{1}H-MRI measurements.[9] The role of hyperpolarized [1-^{13}C]pyruvate in diagnosis and differential diagnosis between normal and cancer tissues have been widely reported, with increased lactate labelling occurring in tumour tissues.[29,30] In the clinic, tumour grading by biopsy can sometimes be difficult given the location and accessibility of the organ of interest, e.g. pancreas. It is for these reasons that transfer of this technique would be interesting, as it would allow not only for more accurately targeted biopsies but also for a potential reduction in biopsy procedures under some circumstances. The few studies that have explored the role of HP [1-^{13}C]pyruvate in grading and prognosis in the prostate have produced promising results.[31,32] Changes in tumour size and burden form the major part of the Response Evaluation Criteria In Solid Tumours (RECIST) criteria, which is a widely used method for assessing treatment response in clinical trials.[33] Numerous studies have demonstrated early decreases in hyperpolarized ^{13}C label exchange between injected [1-^{13}C]pyruvate and the endogenous lactate pool in a range of cancer models following treatment with cytotoxic chemotherapy,[34,35] targeted drugs,[36–38] and radiotherapy[39–41] before any tumour size change was observable.

Examples of potential clinical uses

Pancreatic cancer

Pancreatic cancer (PCa) is one of the most aggressive solid malignancies, which can potentially be cured by surgery, making early diagnosis one of the best options for improving patient survival. Imaging plays an important role in the diagnostic algorithm for PCa,[42] with the preferred imaging studies being DCE-CT or DCE-MRI[43] and endoscopic ultrasonography, which may be useful in patients with equivocal CT/MRI findings.[44] The role of ^{18}F-FDG-PET remains unclear,[43] however its major impact has been in the detection of small metastases[45] and treatment monitoring. A recent study[27] has shown that imaging with hyperpolarized [1-^{13}C]pyruvate could make an impact in the early diagnosis of PCa in high-risk individuals, which are believed to comprise 36% of the cases of PCa.[46–48] Imaging with hyperpolarized [1-^{13}C]pyruvate could also potentially play a role in other clinical challenges in PCa, including differential diagnosis of PCa from chronic pancreatitis; treatment monitoring; and early anatomic detection of tumour recurrence.

Breast cancer

DCE-MRI is the morphological reference imaging modality used in the assessment of breast cancer, with PET playing a growing role in the detection of metastatic lesions. Our increasing understanding